首页> 外文期刊>World journal of urology >Effect of testosterone, raloxifene and estrogen replacement on the microstructure and biomechanics of metaphyseal osteoporotic bones in orchiectomized male rats.
【24h】

Effect of testosterone, raloxifene and estrogen replacement on the microstructure and biomechanics of metaphyseal osteoporotic bones in orchiectomized male rats.

机译:睾丸激素,雷洛昔芬和雌激素替代对睾丸切除后雄性大鼠干phy端骨质疏松骨微结构和生物力学的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: Currently, osteoporosis research is rarely undertaken in males but an increase in male life expectancy in the company of hypogonadism suggests the necessity for potential therapeutic options. MATERIALS AND METHODS: In this study, the changes in bone structure under standardized testosterone- (T), raloxifene- (R) and estrogen (E)-supplemented diets were analyzed in osteoporotic castrated male rats. RESULTS: Unexpected biomechanical results could be only explained by the histomorphometry, but not by BMD measurements obtained from the qCT. All tested substances showed a significant improvement in the trabecular network (trabecular bone area for C: 2.55 mm(2), T: 4.25 mm(2), R: 4.22 mm(2) and E: 4.28 mm(2)), and suggests that the bone structure was preserved. For the metaphyseal cortical bone, a significant loss was detected in T (CBP: 18.7%) compared to R (CBP: 30.0%), E (CBP: 26.8%) and even to the osteoporotic control (CBP: 28.6%). This explains the observed early mechanical final failure after T supplementation. However, due to the preserved trabecular bone in T, the occurrence of the first microfractures (yL: 49 +/- 21.4 N) was significantly later than in the osteoporotic control (yL: 39.5 +/- 15.5 N). Raloxifene performed well in hindering the bone loss associated with osteoporosis. However, its effect (yL: 83.3 +/- 16.5 N) did not approach the protective effect of E (yL: 99.2 +/- 21.1 N). CONCLUSION: Testosterone only preserved the deterioration of the trabecular bone but not of the cortical bone. Raloxifene prevented the bone loss associated with osteoporosis at all bony structures. This effect did not approach the protective effect of estrogen on trabecular bone, but it is more suitable for male individuals because it has no feminizing effects on the subject.
机译:简介:目前,很少在男性中进行骨质疏松症的研究,但是性腺功能减退症患者的男性预期寿命的增加表明了潜在治疗方法的必要性。材料与方法:本研究分析了去骨雄性骨质疏松大鼠在补充标准睾丸激素(T),雷洛昔芬(R)和雌激素(E)饮食下的骨结构变化。结果:意想不到的生物力学结果只能通过组织形态学来解释,而不能通过从qCT获得的BMD测量来解释。所有测试的物质均显示了小梁网络的显着改善(C的小梁骨面积:2.55 mm(2),T:4.25 mm(2),R:4.22 mm(2)和E:4.28 mm(2)),以及提示骨骼结构得以保留。对于干phy端皮质骨,与R(CBP:30.0%),E(CBP:26.8%)甚至骨质疏松症对照(CBP:28.6%)相比,T(CBP:18.7%)明显减少。这解释了在补充T后观察到的早期机械最终衰竭。但是,由于T中保留了小梁骨,因此第一个微骨折的发生(yL:49 +/- 21.4 N)明显晚于骨质疏松症对照组(yL:39.5 +/- 15.5 N)。雷洛昔芬在阻止与骨质疏松症有关的骨质流失方面表现良好。但是,其效果(yL:83.3 +/- 16.5 N)没有达到E的保护作用(yL:99.2 +/- 21.1 N)。结论:睾丸激素只能保留小梁骨的退化,而不能保留皮质骨的退化。雷洛昔芬预防了所有骨结构中与骨质疏松症相关的骨质流失。该作用没有达到雌激素对小梁骨的保护作用,但是由于它对受试者没有女性化作用,因此它更适合男性个体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号